Monitor the ESMO 2026 presentation in October for EVX-01 three-year data, which is the key near-term catalyst. Cash runway into H2 2027 reduces near-term dilution risk, but the company remains pre-revenue and will need additional capital before then. Partnership discussions are ongoing but unconfirmed.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 20 $3.28entry
- T+1 · 3mo ago +0.91%α +0.51% · $3.31
- T+5 · 3mo ago −3.96%α −5.08% · $3.15
- T+20 · 2mo ago −0.30%α −0.30% · $3.27
- T+60 · 4d ago −16.46%α −15.38% · $2.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion reported Q2 2026 net loss of $3.7M, in line with expectations and improved from $4.8M a year ago, with cash of $14.0M funding operations into H2 2027. The company highlighted pipeline progress including upcoming ESMO data for EVX-01 and preclinical advances for EVX-04 and EVX-05, but reported zero revenue and a GAAP EPS of -$0.01, which was a 4900% miss vs the -$0.01 consensus estimate due to a rounding artifact on a tiny base. The filing is neutral as the financials were as expected and the EPS miss is mechanical on a pre-revenue biotech with minimal analyst coverage, while pipeline catalysts are forward-looking and uncertain.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $3.7M vs $4.8M in Q2 2025, in line with expectations
- Cash and cash equivalents of $14.0M as of June 30, 2026, providing runway into H2 2027
- R&D expenses of $2.3M, G&A of $1.5M, both aligned with Q1 2026
- Zero revenue reported; GAAP EPS of -$0.01 vs consensus of -$0.01 (miss of -4900% is a mechanical artifact of a tiny base)
- Pipeline catalysts: three-year EVX-01 data at ESMO 2026, preclinical progress on EVX-04 and EVX-05, and EVX-V1 CMV vaccine data
Financial Impact
Net loss improved 22% YoY to $3.7M; cash burn $4.4M in Q2 2026; no revenue generated
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- Cash runway only into H2 2027; likely need for additional financing
- Pipeline candidates are early-stage (preclinical/Phase 2) with high clinical risk
- EPS miss of -4900% is a rounding artifact but may spook algorithmic traders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3348249 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers